Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial

Smith, 2014, Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource, Hepatology, 59, 318, 10.1002/hep.26744 Messina, 2015, Global distribution and prevalence of hepatitis C virus genotypes, Hepatology, 61, 77, 10.1002/hep.27259 Asselah, 2017, Eliminating hepatitis C within low-income countries—the need to cure genotypes 4, 5, 6, J Hepatol Boyd, 2018, HCV genotype 4, 5 and 6: distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens, J Viral Hepat, 25, 969, 10.1111/jvh.12896 Thong, 2014, Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication, World J Gastroenterol, 20, 2927, 10.3748/wjg.v20.i11.2927 Li, 2014, Nine additional complete genome sequences of HCV genotype 6 from Vietnam including new subtypes 6xb and 6xc, Virology, 468–470, 172, 10.1016/j.virol.2014.08.006 Li, 2015, An expanded taxonomy of hepatitis C virus genotype 6: characterization of 22 new full-length viral genomes, Virology, 476, 355, 10.1016/j.virol.2014.12.025 2017 Ng, 2018, In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir, Antimicrob Agents Chemother, 62, e01620, 10.1128/AAC.01620-17 Ng, 2017, In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir, Antimicrob Agents Chemother, 61, e02558, 10.1128/AAC.02558-16 Reau, 2018, Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection, Hepatology, 68, 1298, 10.1002/hep.30046 Rockstroh, 2018, Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 Study, Clin Infect Dis, 67, 1010, 10.1093/cid/ciy220 Forns, 2017, Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial, Lancet Infect Dis, 17, 1062, 10.1016/S1473-3099(17)30496-6 Asselah, 2018, Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis, Clin Gastroenterol Hepatol, 16, 417, 10.1016/j.cgh.2017.09.027 Kwo, 2017, Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis, J Hepatol, 67, 263, 10.1016/j.jhep.2017.03.039 Gane, 2017, Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment, N Engl J Med, 377, 1448, 10.1056/NEJMoa1704053 Puoti, 2018, High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1-6 patients without cirrhosis, J Hepatol, 69, 293, 10.1016/j.jhep.2018.03.007 Chao, 2011, Systematic review: epidemiology of hepatitis C genotype 6 and its management, Aliment Pharmacol Ther, 34, 286, 10.1111/j.1365-2036.2011.04714.x George, 2018, Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection, Hepatol Commun, 2, 595, 10.1002/hep4.1177 2018, EASL Recommendations on Treatment of Hepatitis C 2018, J Hepatol, 69, 461, 10.1016/j.jhep.2018.03.026 Feld, 2015, Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection, N Engl J Med, 373, 2599, 10.1056/NEJMoa1512610 Abergel, 2016, Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study, Lancet Infect Dis, 16, 459, 10.1016/S1473-3099(15)00529-0 Gane, 2015, Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection, Gastroenterology, 149, 1454, 10.1053/j.gastro.2015.07.063 Bourliere, 2017, Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection, N Engl J Med, 376, 2134, 10.1056/NEJMoa1613512 Jacobson, 2017, Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials, Gastroenterology, 153, 113, 10.1053/j.gastro.2017.03.047 D'Ambrosio, 2018, Real-life effectiveness and safety of glecaprevir/pibrentasvir among 723 Italian patients with chronic hepatitis C: the Navigator-II study, J Hepatol, 68, S65, 10.1016/S0168-8278(18)30351-9 Berg, 2018, First real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: data from the German Hepatitis C-Registry, J Hepatol, 68, S37, 10.1016/S0168-8278(18)30290-3